Pneumomediastinum in a patient with COVID-19 due to diffuse alveolar damage

Frank Heijboer; Laurien Oswald; Sander Cretier; Gert Jan Braunstahl

doi:10.1136/bcr-2021-242527

Pneumomediastinum in a patient with COVID-19 due to diffuse alveolar damage

Frank Heijboer, Laurien Oswald, Sander Cretier, Gert Jan Braunstahl^*

^*Corresponding author for this work

Pulmonary Medicine

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

3 Downloads (Pure)

Abstract

A 74-year-old man with COVID-19 was admitted and experienced progressive dyspnoea while receiving supplemental oxygen via high-flow nasal cannula (HFNC). A CT of the thorax showed a pneumomediastinum. The HFNC was temporally interrupted, since it was uncertain whether the positive end-expiratory pressure of the HFNC could be the cause of the pneumomediastinum. After restart of the HFNC, there was no increase of symptoms. We suggest that the pneumomediastinum was the result of COVID-19-related alveolar damage, and not due to the use of HFNC. This observation is relevant since HFNC is often used in the treatment of severe COVID-19 pneumonia.

Original language	English
Article number	e242527
Pages (from-to)	1-4
Journal	BMJ Case Reports
Volume	14
Issue number	5
Early online date	11 May 2021
DOIs	https://doi.org/10.1136/bcr-2021-242527
Publication status	Published - 2021

Bibliographical note

Publisher Copyright:
© BMJ Publishing Group Limited 2021. Re-use permitted under CC BY. Published by BMJ.

Access to Document

10.1136/bcr-2021-242527Licence: CC BY

e242527.fullFinal published version, 1.47 MBLicence: CC BY

Cite this

@article{bec2afeb958f4e7e92d8ced654a0957c,

title = "Pneumomediastinum in a patient with COVID-19 due to diffuse alveolar damage",

abstract = "A 74-year-old man with COVID-19 was admitted and experienced progressive dyspnoea while receiving supplemental oxygen via high-flow nasal cannula (HFNC). A CT of the thorax showed a pneumomediastinum. The HFNC was temporally interrupted, since it was uncertain whether the positive end-expiratory pressure of the HFNC could be the cause of the pneumomediastinum. After restart of the HFNC, there was no increase of symptoms. We suggest that the pneumomediastinum was the result of COVID-19-related alveolar damage, and not due to the use of HFNC. This observation is relevant since HFNC is often used in the treatment of severe COVID-19 pneumonia.",

author = "Frank Heijboer and Laurien Oswald and Sander Cretier and Braunstahl, {Gert Jan}",

note = "Publisher Copyright: {\textcopyright} BMJ Publishing Group Limited 2021. Re-use permitted under CC BY. Published by BMJ.",

year = "2021",

doi = "10.1136/bcr-2021-242527",

language = "English",

volume = "14",

pages = "1--4",

journal = "BMJ Case Reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

number = "5",

}

TY - JOUR

T1 - Pneumomediastinum in a patient with COVID-19 due to diffuse alveolar damage

AU - Heijboer, Frank

AU - Oswald, Laurien

AU - Cretier, Sander

AU - Braunstahl, Gert Jan

N1 - Publisher Copyright: © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY. Published by BMJ.

PY - 2021

Y1 - 2021

N2 - A 74-year-old man with COVID-19 was admitted and experienced progressive dyspnoea while receiving supplemental oxygen via high-flow nasal cannula (HFNC). A CT of the thorax showed a pneumomediastinum. The HFNC was temporally interrupted, since it was uncertain whether the positive end-expiratory pressure of the HFNC could be the cause of the pneumomediastinum. After restart of the HFNC, there was no increase of symptoms. We suggest that the pneumomediastinum was the result of COVID-19-related alveolar damage, and not due to the use of HFNC. This observation is relevant since HFNC is often used in the treatment of severe COVID-19 pneumonia.

AB - A 74-year-old man with COVID-19 was admitted and experienced progressive dyspnoea while receiving supplemental oxygen via high-flow nasal cannula (HFNC). A CT of the thorax showed a pneumomediastinum. The HFNC was temporally interrupted, since it was uncertain whether the positive end-expiratory pressure of the HFNC could be the cause of the pneumomediastinum. After restart of the HFNC, there was no increase of symptoms. We suggest that the pneumomediastinum was the result of COVID-19-related alveolar damage, and not due to the use of HFNC. This observation is relevant since HFNC is often used in the treatment of severe COVID-19 pneumonia.

UR - http://www.scopus.com/inward/record.url?scp=85105710979&partnerID=8YFLogxK

U2 - 10.1136/bcr-2021-242527

DO - 10.1136/bcr-2021-242527

M3 - Article

C2 - 33975848

AN - SCOPUS:85105710979

VL - 14

SP - 1

EP - 4

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

IS - 5

M1 - e242527

ER -

Pneumomediastinum in a patient with COVID-19 due to diffuse alveolar damage

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this